NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30
NANOVIRICIDES, INC.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026
$1.30−0.08 (-5.80%)
Close on Oct 19, 2026
- Market cap
- $28.93M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -47.5% | -34.1% | -101.5% | |
| Return on assets | -32.4% | -32.6% | -87.9% | |
| Current ratio | 3.28 | 59.30 | 2.66 | |
| Interest coverage | -12.3× | -102.4× | – | |
| Diluted shares | 3M | 11M | 20M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Nanoviricides generated $34.05M from operations and spent $773.90K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$34.05M
Used
$773.90K
Capital expenditure$773.90K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 7 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.22M
- Cash generatingOperating cash flow above zero-$7.70M
- Return on assets improvedROA up on the prior year-73.8% → -93.1%
- Earnings backed by cashOperating cash flow above net income-$7.70M vs -$8.22M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.28 → 2.66
- No dilutionShare count did not rise15M → 20M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00